Dash Acquisitions Inc. Acquires 1,312 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Dash Acquisitions Inc. increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 30,901 shares of the medical research company’s stock after buying an additional 1,312 shares during the period. Thermo Fisher Scientific comprises about 4.6% of Dash Acquisitions Inc.’s investment portfolio, making the stock its 9th largest position. Dash Acquisitions Inc.’s holdings in Thermo Fisher Scientific were worth $19,114,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in TMO. BDF Gestion acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at approximately $6,368,000. Nisa Investment Advisors LLC lifted its position in shares of Thermo Fisher Scientific by 6.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 140,708 shares of the medical research company’s stock worth $87,093,000 after buying an additional 8,180 shares during the last quarter. Lord Abbett & CO. LLC boosted its holdings in shares of Thermo Fisher Scientific by 1.9% in the 1st quarter. Lord Abbett & CO. LLC now owns 78,247 shares of the medical research company’s stock valued at $45,478,000 after buying an additional 1,480 shares during the period. Advisors Capital Management LLC raised its stake in Thermo Fisher Scientific by 5.8% during the first quarter. Advisors Capital Management LLC now owns 111,169 shares of the medical research company’s stock worth $64,613,000 after acquiring an additional 6,089 shares during the period. Finally, Seven Eight Capital LP bought a new position in Thermo Fisher Scientific in the first quarter worth about $1,161,000. 89.23% of the stock is currently owned by institutional investors.

Insider Transactions at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $168,048.00. Following the completion of the sale, the executive vice president now owns 16,663 shares in the company, valued at approximately $9,333,946.08. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the transaction, the senior vice president now directly owns 12,736 shares of the company’s stock, valued at approximately $7,134,197.76. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $168,048.00. Following the completion of the sale, the executive vice president now owns 16,663 shares of the company’s stock, valued at approximately $9,333,946.08. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 12,300 shares of company stock valued at $6,831,268 over the last ninety days. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Trading Up 2.1 %

Shares of NYSE:TMO opened at $557.92 on Friday. The stock has a market capitalization of $213.13 billion, a price-to-earnings ratio of 34.98, a PEG ratio of 3.61 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 1-year low of $437.26 and a 1-year high of $627.88. The company has a 50 day moving average price of $599.39 and a 200 day moving average price of $583.31. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.25 by $0.03. The company had revenue of $10.60 billion for the quarter, compared to analyst estimates of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. Thermo Fisher Scientific’s revenue for the quarter was up .2% compared to the same quarter last year. During the same period in the previous year, the firm earned $5.69 earnings per share. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Stifel Nicolaus cut their price target on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. Redburn Atlantic initiated coverage on shares of Thermo Fisher Scientific in a report on Monday, October 14th. They set a “buy” rating and a $680.00 price target for the company. Sanford C. Bernstein dropped their price objective on shares of Thermo Fisher Scientific from $625.00 to $620.00 and set a “market perform” rating on the stock in a report on Thursday, October 24th. JPMorgan Chase & Co. boosted their target price on shares of Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an “overweight” rating in a research note on Friday, September 20th. Finally, Royal Bank of Canada cut their price target on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $649.33.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.